Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Study Summary

This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.

Conditions

Advanced Malignant Neoplasm Pigmented Villonodular Synovitis Giant Cell Tumor of Tendon Sheath Tenosynovial Giant Cell Tumor Tenosynovial Giant Cell Tumor, Diffuse

Interventions / Drugs

Vimseltinib

View on ClinicalTrials.gov ↗

Sponsor

DCPH

Deciphera Pharmaceuticals

Oncology

D40/100

Study Details

Enrollment120 participants

Primary Completion—

Lead SponsorDeciphera Pharmaceuticals, LLC

Data Retrieved2026-04-11 04:11:28.433244+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.